Conversion to Tacrolimus and Atorvastatin in Cyclosporine-treated Heart Transplant Recipients With Dyslipidemia Refractory to Fluvastatin

Journal of Heart and Lung Transplantation

Volumn 28, Issue 6, 2009, Pages 598-604

  Skalicka, Blanka ^a   Kubanek, Milos ^a   Malek, Ivan ^a   Vymetalova, Yevheniya ^a   Hoskova, Lenka ^a   Podzimkova, Mariana ^a   Kautzner, Josef ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; ATORVASTATIN; AZATHIOPRINE; CHOLESTEROL; CREATINE KINASE; CYCLOSPORIN A; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; AGED; ANXIETY; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HEART GRAFT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INDIGESTION; KIDNEY DYSFUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; MYOPATHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SIDE EFFECT; SORE THROAT; THROMBOCYTE COUNT; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; COHORT STUDIES; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FATTY ACIDS, MONOUNSATURATED; FEMALE; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HEPTANOIC ACIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; TACROLIMUS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 65749094012     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.03.014     Document Type: Article

References (29)

1. Miller L.W., Schlant R.C., Kobashigawa J., et al. 24th Bethesda Conference: Cardiac transplantation. Task Force 5: Complications. J Am Coll Cardiol 22 (1993) 41-54
2. Keogh A.M., Valantine H.A., Hunt S.A., et al. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant 11 (1992) 892-901
3. Weis M., and von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation 96 (1997) 2069-2077
4. Orbaek Andersen H. Heart allograft vascular disease: an obliterative vascular disease in transplanted heart. Atherosclerosis 142 (1999) 243-263
5. Escobar A., Ventura H.O., Stapleton D.D., et al. Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol 74 (1994) 1042-1046
6. Smauss D., and Weis M. Cardiac allograft vasculopathy. Circulation 117 (2008) 2131-2141
7. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 (1995) 621-627
8. Kobashigawa J.A., Moriguchi J.D., Laks H., et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 24 (2005) 1736-1740
9. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 96 (1997) 1398-1402
10. Wenke K., Meiser B., Thiery J., et al. Impact of simvastatin therapy after heart transplantation an 11-year prospective evaluation. Herz 30 (2005) 431-432
11. Ballantyne C.M., Corsini A., Davidson M.H., et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163 (2003) 553-564
12. Omar M.A., and Wilson J.P. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 36 (2002) 288-295
13. Bilchick K.C., Henrikson C.A., Skojec D., et al. Treatment of hyperlipidaemia in cardiac transplant recipients. Am Heart J 148 (2004) 200-210
14. Lindenfeld J., Page R.L., Zolty R., et al. Drug therapy in heart transplant recipient. Circulation 111 (2005) 113-117
15. Spinarova L., and Toman J. Fluvastatin in patients after transplantation of the heart. Vnitr Lek 44 (1998) 13-16
16. Jones P., Kafonek S., Laurora I., et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81 (1998) 582-587
17. Magnani G., Carinci V., Magelli C., et al. Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin. J Heart Lung Transplant 19 (2000) 710-715
18. Patel D.N., Pagani F.D., Koelling T.M., et al. Safety and efficacy of atorvastatin in heart transplant recipients. J Heart Lung Transplant 21 (2002) 204-210
19. Lemahieu W.P., Hermann M., Asberg A., et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 5 (2005) 2236-2243
20. Stewart S., Winters G.L., Fishbein M.C., et al. Revision of the 1990 working formulation for the Standardization of Nomenclature in the Diagnosis of Heart Rejection. J Heart Lung Transplant 24 (2005) 1710-1720
21. Keogh A., MacDonald P., Kaan A., et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 19 (2000) 529-537
22. Mehra M.R., Uber P.A., Vivekananthan K., et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 40 (2002) 1609-1614
23. Holdaas H., Fellstroem B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 (2003) 2024-2031
24. Samman A., Imai C., Straatman L., et al. Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients. J Heart Lung Transplant 24 (2005) 1008-1013
25. Quarta C.C., Potena L., Grigioni F., et al. Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients. J Heart Lung Transplant 27 (2008) 685-688
26. Lubitz S.A., Pinney S., Wisnivesky J.P., et al. Statin therapy associated with a reduced risk of chronic renal failure after cardiac transplantation. J Heart Lung Transplant 26 (2007) 264-272
27. MRC/BHF. Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
28. Hermann M., Asberg A., Christensen H., et al. Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clin Pharmacol Ther 76 (2004) 388-391
29. Taylor D.O., Barr M.L., Radovancevic B., et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 18 (1999) 336-345